Intracameral moxifloxacin: In vitro safety on human ocular cells

Cornea

Volumn 28, Issue 5, 2009, Pages 553-561

  Kernt, Marcus ^a   Neubauer, Aljoscha S ^a   Liegl, Raffael G ^a   Lackerbauer, Carl A ^a   Eibl, Kirsten H ^a   Alge, Claudia S ^a   Ulbig, Michael W ^a   Kampik A, Anselm ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibiotics; Endophthalmitis; Fluoroquinolones; Intracameral drug delivery; Moxifloxacin

Indexed keywords

HYDROGEN PEROXIDE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MOXIFLOXACIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CYTOTOXICITY; DRUG SAFETY; EYE INFLAMMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACAMERAL DRUG ADMINISTRATION; LONG TERM EXPOSURE; ORGAN CULTURE; OXIDATIVE STRESS; PIGMENT CELL; PRIORITY JOURNAL; TOXICITY TESTING; TRABECULAR MESHWORK;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, CORNEAL; EYE; HUMANS; QUINOLINES; RETINAL PIGMENT EPITHELIUM; TRABECULAR MESHWORK;

EID: 67650613989     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318191447b     Document Type: Article

References (57)

1. Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004;122:487-494.
2. Aaberg TM Jr, Flynn HW Jr, Schiffman J, et al. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology. 1998;105:1004-1010.
3. Javitt JC, Street DA, Tielsch JM, et al. National outcomes of cataract extraction. Retinal detachment and endophthalmitis after outpatient cataract surgery. Cataract Patient Outcomes Research Team. Ophthalmology. 1994;101:100-105; discussion 106.
4. Miller JJ, Scott IU, Flynn HW Jr, et al. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005;139:983-987.
5. Endophthalmitis Study Group, European Society of Cataract and Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978-988.
6. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123:613-620.
7. West ES, Behrens A, McDonnell PJ, et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology. 2005;112: 1388-1394.
8. Masket S. Preventing, diagnosing, and treating endophthalmitis. J Cataract Refract Surg. 1998;24:725-726.
9. Axer-Siegel R, Stiebel-Kalish H, Rosenblatt I, et al. Cystoid macular edema after cataract surgery with intraocular vancomycin. Ophthalmology. 1999;106:1660-1664.
10. Villada JR, Vicente U, Javaloy J, et al. Severe anaphylactic reaction after intracameral antibiotic administration during cataract surgery. J Cataract Refract Surg. 2005;31:620-621.
11. Filip M, Dragne C, Filip A, et al. Toxic anterior segment syndrome [in Romanian]. Oftalmologia. 2006;50:27-29.
12. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113:1479-1496.
13. Aaberg TM Jr, Flynn HW Jr, Murray TG. Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. Arch Ophthalmol. 1994;112:18-19.
14. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004;49(Suppl 2):S73-S78.
15. Benz MS, Scott IU, Flynn HW Jr, et al. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol. 2004;137:38-42.
16. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1-17.
17. Kunimoto DY, Das T, Sharma S, et al. Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol. 1999;128:240-242.
18. Callegan MC, Ramirez R, Kane ST, et al. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003;20:246-252.
19. Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140:497-504.
20. Ermis SS, Cetinkaya Z, Kiyici H, et al. Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis. Curr Eye Res. 2007;32:337-344.
21. Ermis SS, Cetinkaya Z, Kiyici H, et al. Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model. Tohoku J Exp Med. 2005;205:223-229.
22. Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg. 2007;33:63-68.
23. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749-3752.
24. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491-503.
25. Feys J, Emond JP, Salvanet-Bouccara A, et al. Interleukin-6 and other cytokines in the aqueous humor in uveitis and endophthalmitis [in French]. J Fr Ophtalmol. 1994;17:634-639.
26. Bourne WM, Kaufman HE. The endothelium of clear corneal transplants. Arch Ophthalmol. 1976;94:1730-1732.
27. Bohnke M. A new system for storing donor corneas [in German]. Klin Monatsbl Augenheilkd. 1991;198:135-137.
28. Bednarz J, Teifel M, Friedl P, et al. Immortalization of human corneal endothelial cells using electroporation protocol optimized for human corneal endothelial and human retinal pigment epithelial cells. Acta Ophthalmol Scand. 2000;78:130-136.
29. Miller PE, Stanz KM, Dubielzig RR, et al. Mechanisms of acute intraocular pressure increases after phacoemulsification lens extraction in dogs. Am J Vet Res. 1997;58:1159-1165.
30. Laurell CG, Lydahl E. Evaluation of aqueous outflow facility in patients with high intraocular pressure after cataract surgery. Ophthalmic Surg Lasers Imaging. 2006;37:476-480.
31. Siegner A, May CA, Welge-Lussen UW, et al. Alpha B-crystallin in the primate ciliary muscle and trabecular meshwork. Eur J Cell Biol. 1996;71: 165-169.
32. Welge-Lussen U, Eichhorn M, Bloemendal H, et al. Classification of human scleral spur cells in monolayer culture. Eur J Cell Biol. 1998;75:78-84.
33. Haritoglou C, Yu A, Freyer W, et al. An evaluation of novel vital dyes for intraocular surgery. Invest Ophthalmol Vis Sci. 2005;46:3315-3322.
34. Kernt M, Neubauer AS, Ulbig MW, et al. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg. 2008;34:480-488.
35. Tu KL, Kaye SB, Sidaras G, et al. Effect of intraocular surgery and ketamine on aqueous and serum cytokines. Mol Vis. 2007;13:1130-1137.
36. Kawashima H. Chemokines - their role in immunotherapy for intraocular inflammation. Ocul Immunol Inflamm. 2003;11:83-90.
37. Giese MJ, Sumner HL, Berliner JA, et al. Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci. 1998;39:2785-2790.
38. Mo JS, Streilein JW. Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol. 2001;31:3806-3815.
39. Satofuka S, Ichihara A, Nagai N, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci. 2006;47:2686-2692.
40. Thomas J, Kanangat S, Rouse BT. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J Interferon Cytokine Res. 1998;18:681-690.
41. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
42. Smith A, Pennefather PM, Kaye SB, et al. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747-761.
43. Mather R, Karenchak LM, Romanowski EG, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
44. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'. J Antimicrob Chemother. 1999;43(Suppl B):l-ll.
45. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.
46. Aydin E, Kazi AA, Peyman GA, et al. Intravitreal toxicity of moxifloxacin. Retina. 2006;26:187-190.
47. O'Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg. 2007;33:1790-1800.
48. Hammoudi DS, Abdolell M, Wong DT. Patterns of perioperative prophylaxis for cataract surgery in Canada. Can J Ophthalmol. 2007; 42:681-688.
49. Koss MJ, Eder M, Blumenkranz MS, et al. The effectiveness of the new fluoroquinolones against the normal bacterial flora of the conjunctiva [in German]. Ophthalmologe. 2007;104:21-27.
50. McCulley JP, Caudle D, Aronowicz JD, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006;113:955-959.
51. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005;123:39-44.
52. Gao H, Pennesi ME, Qiao X, et al. Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci. 2006;47:1606-1611.
53. Deramo VA, Lai JC, Fastenberg DM, et al. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol. 2006;142:721.
54. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106:1313-1318.
55. Schentag JJ. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J Chemother. 2002;14(Suppl 2):13-21.
56. Metzler K, Hansen GM, Hedlin P, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents. 2004;24:161-167.
57. Mamalis N, Edelhauser HF, Dawson DG, et al. Toxic anterior segment syndrome. J Cataract Refract Surg. 2006;32:324-333.